drug
Daptomycin Novo
Marketedupdated 3mo agoby Xellia Pharmaceuticals USA LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- tagApproval18 co-mentions · 9 sources
- drugDaptomycin Nichi-Iko12 co-mentions · 12 sources
- drugDapzura RT12 co-mentions · 12 sources
- drugDAPTOMYCIN12 co-mentions · 12 sources
- tagAdCom2 co-mentions · 2 sources
- tag510(k) Clearance2 co-mentions · 2 sources
- company$TMOTHERMO FISHER SCIENTIFIC INC.1 co-mentions · 1 sources
all catalysts(9)
approval · 9
Jul 12, 2019
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Jun 29, 2021
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Jun 29, 2021
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Nov 13, 2022
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Nov 13, 2022
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Mar 22, 2023
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Jan 26, 2026
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Jan 30, 2026
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Mar 13, 2026
approval
DAPTOMYCIN — FDA approval
Daptomycin Novo
→
Trials studying Daptomycin Novo
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 4, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Mar 11, 2041formulationUS 11173189
- Aug 28, 2038formulationUS 11759497
- Aug 28, 2038formulationUS 11759497
- Aug 28, 2038method-of-use (U-3981)US 12053502
- Aug 28, 2038method-of-use (U-3981)US 12053502
- Sep 11, 2033formulationUS 10357535
- Sep 11, 2033formulationUS 10357535
- Sep 11, 2033formulationUS 9655946
- Sep 11, 2033formulationUS 9655946
- Nov 23, 2030formulationUS 91384564.3y
- Sep 4, 2028method-of-use (U-1180)US 80036732.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that